NasdaqGS - Delayed Quote USD

Innate Pharma S.A. (IPHA)

2.4400 +0.0400 (+1.67%)
At close: April 19 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Herve Brailly Ph.D. Co-Founder, Interim CEO & Chairman of Executive Board -- -- 1961
Mr. Yannis Morel Ph.D. Executive VP, COO & Member of Executive Board 383.08k -- 1973
Dr. François Romagné Ph.D. Founder -- -- 1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. Founder, Senior VP & Chief Scientific Officer -- -- 1964
Dr. Marc Bonneville Ph.D. Founder -- -- 1960
Mr. Jean Jacques Fournié Ph.D. Founder -- -- --
Mr. Alessandro Moretta M.D., Ph.D. Founder -- -- --
Mr. Frederic Lombard M.B.A. Senior VP & CFO -- -- 1975
Dr. Sonia Quaratino M.D., Ph.D. Executive VP, Chief Medical Officer & Member of Executive Board -- -- 1967
Mr. Arvind Sood Executive VP, President of US Operations & Member of Executive Board -- -- --

Innate Pharma S.A.

117, Avenue de Luminy
BP 30191
Marseille, 13009
France
33 4 30 30 30 30 https://www.innate-pharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
179

Description

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Corporate Governance

Innate Pharma S.A.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

MOLN Molecular Partners AG
3.3200
-8.79%
 
SABS SAB Biotherapeutics, Inc.
4.2900
-2.72%
 
CSBR Champions Oncology, Inc.
5.06
+0.60%
 
BPTS Biophytis S.A.
0.2901
-7.90%
 
ARTL Artelo Biosciences, Inc.
1.3150
+2.73%
 
LABP Landos Biopharma, Inc.
21.82
+0.28%
 
PRTC PureTech Health plc
26.15
-0.46%
 
TBPH Theravance Biopharma, Inc.
9.34
+1.52%
 
CYCC Cyclacel Pharmaceuticals, Inc.
1.7800
-4.30%
 
VIGL Vigil Neuroscience, Inc.
2.8200
+2.55%